Health Science Center’s President’s Gala to help establish Institute for Alzheimer and Neurodegenerative Medicine

Breaking News
6024

Translate to Spanish or other 102 languages!

William L. Henrich, M.D., president of the UT Health Science Center San Antonio, visits with Alonzo Cantu, president of Cantu Construction.
William L. Henrich, M.D., president of the UT Health Science Center San Antonio, visits with Alonzo Cantu, president of Cantu Construction.

Mega Doctor News

- Advertisement -

William L. Henrich, M.D., president of the UT Health Science Center San Antonio, visits with Alonzo Cantu, president of Cantu Construction. The two were attending the Health Science Center’s President’s Gala held Sept. 26, which will help establish South Texas’ first Institute for Alzheimer and Neurodegenerative Medicine. the new institute is expected to open in 2016.

William L. Henrich, M.D., president of the UT Health Science Center San Antonio, left, is seen with with Alonzo Cantu, president of Cantu Construction.

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Valley Grande Institute’s expansion to Raymondville brings new vocational medical educational programs
Next article
Mesothelioma Cases are Steadily Increasing, Notes Mesothelioma Website

More Articles

FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk 

The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” 

Embolism Treatment Developed at University of Michigan receives FDA clearance 

Patients with persistent blood clots require frequent medical interventions just to survive. Yet despite this critical need, there have been few advancements in how these patients are treated. 

FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women

The U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week. The approval aligns with FDA’s Public Health Pillar: Increasing Access to Affordable Medicines & Medical Products.

FDA Approves Immunotherapy Regimen Studied by Mayo Clinic for Stage 3 Colon Cancer

The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair, or dMMR.
- Advertisement -